On December 4, 2020, PsyBio Therapeutics, Inc. and Leo Acquisitions Corp. closed a brokered private placement of subscription receipts of PsyBio Therapeutics Financing Inc., a special purpose British Columbia company incorporated solely for the purpose of the financing and wholly-owned by the Chief Executive Officer of PsyBio, at a price of $0.35 per subscription receipt for aggregate gross proceeds of approximately $14.5 million. The financing was completed in connection with a series of transactions that will result in the reverse takeover of Leo by the shareholders of PsyBio.
Eight Capital acted as lead agent together with Canaccord Genuity Corp.
Cassels acted for Eight Capital with a deal team that included Nancy Choi, David Singh and Reza Sarsangi (Securities) and Chandimal Nicholas (Intellectual Property and Regulatory).